WTX-245

WTX-245 is a first-in-class, small molecule inhibitor developed by WaveBreak that targets the aggregation of TDP-43 protein, a pathological hallmark in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 is essential for mRNA processing in motor neurons; its cytoplasmic aggregation leads to loss of nuclear function, widespread transcriptional dysregulation, and neuronal death. WTX-245 was designed to directly inhibit disease-specific nucleation mechanisms at the source of TDP-43 aggregation. In preclinical neuronal cell models mimicking ALS pathology, WTX-245 significantly reduced cytoplasmic TDP-43 aggregates, restored normal transcriptional regulation across multiple mRNAs critical for motor neuron survival (including UNC13A and STMN2), and reduced mis-splicing events. These findings suggest disease-modifying potential for ALS and FTD by protecting or restoring motor neuron function through direct inhibition of pathogenic protein aggregation[1][2][3][5].